AFP and hepatocellular carcinoma: Although in this trial second-line treatment with ramucirumab did not show an improvement in OS for patients with advanced HCC when compared with placebo in an unselected population, investigators were able to identify a pre-planned subgroup—patients with elevated AFP values (AFP ≥400 ng/mL)—that benefited from ramucirumab treatment.